Renal denervation with ultrasound therapy (paradise device) is an effective therapy for systemic hypertension.

Hypertension is the most important risk factor for cardiovascular events associated morbidity and mortality, affecting more than one billion people worldwide (1). Although anti-hypertensive drug therapy is very effective in reducing the risk of cardiovascular disease and death, approximately 10% of patients suffer from resistant hypertension despite at least three maximally tolerated doses of anti-hypertensive drugs including a diuretic (2).

[1]  Neil Chapman,et al.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial , 2018, The Lancet.

[2]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[3]  R. Virmani,et al.  Controlled circumferential renal sympathetic denervation with preservation of the renal arterial wall using intraluminal ultrasound: a next-generation approach for treating sympathetic overactivity. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  Deepak L. Bhatt,et al.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.

[5]  R. Virmani,et al.  Anatomic assessment of sympathetic peri-arterial renal nerves in man. , 2014, Journal of the American College of Cardiology.

[6]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[7]  Michael Böhm,et al.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study , 2014, The Lancet.

[8]  Deepak L. Bhatt,et al.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. , 2012, European heart journal.

[9]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[10]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.